Immune Checkpoint Inhibitors | Real World Brand Tracker | US | 2019
Immune checkpoint inhibitors continue to revolutionize current oncology treatment. Driven by Decision Resources Group’s in-house oncology experts and robust real-world data capabilities, the Real World Brand Tracker captures U.S. claims data to uncover shifting market dynamics and the impact of events on the immune checkpoint inhibitor space, in order to help refine your oncology brand strategies. We cover every approved immune checkpoint inhibitor for every approved oncology indication and monitor the trends in use and reimbursement dynamics over time.
Questions answered:
- How is the uptake for individual immune checkpoint inhibitor brands changing over time?
- Which brand is winning, and how does that vary by indication?
- How does the dynamic regulatory environment for immune checkpoint inhibitors in the U.S. affect prescribing patterns of currently approved immune checkpoint inhibitors by indication?
- What is the average claim charge for each immune checkpoint inhibitor brand and how much if the claim is paid?
- In which type of facilities are patients receiving immune checkpoint inhibitors?
Related Market Assessment Reports
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
